Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Leerink Partners Analyst Says

Guardant Health (NASDAQ:GH) had its price objective raised by stock analysts at Leerink Partners from $170.00 to $180.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners’ price target points to a potential upside of 74.59% from the company’s previous close.

Several other analysts also recently issued reports on the company. Canaccord Genuity Group raised their target price on shares of Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday. BTIG Research increased their price objective on shares of Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a report on Friday. UBS Group restated a “buy” rating and set a $175.00 price objective on shares of Guardant Health in a research report on Friday, January 30th. Evercore set a $110.00 target price on Guardant Health in a research report on Friday. Finally, JPMorgan Chase & Co. increased their price target on Guardant Health from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Friday. Twenty-one analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $117.43.

Guardant Health Price Performance

GH opened at $103.10 on Friday. The firm has a market cap of $12.99 billion, a PE ratio of -31.15 and a beta of 1.63. Guardant Health has a 1 year low of $34.88 and a 1 year high of $120.74. The stock has a 50-day moving average price of $106.69 and a 200-day moving average price of $86.22.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. During the same quarter in the previous year, the firm posted ($0.62) earnings per share. The firm’s revenue was up 39.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Guardant Health will post -2.9 EPS for the current year.

Insider Activity

In related news, insider Terilyn J. Monroe sold 55,167 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $105.97, for a total value of $5,846,046.99. Following the completion of the transaction, the insider owned 20,920 shares in the company, valued at $2,216,892.40. This trade represents a 72.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Chris Freeman sold 31,452 shares of Guardant Health stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $103.07, for a total value of $3,241,757.64. Following the sale, the insider directly owned 25,987 shares of the company’s stock, valued at $2,678,480.09. This trade represents a 54.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 434,511 shares of company stock worth $45,580,887 over the last quarter. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Guardant Health

Several hedge funds have recently bought and sold shares of GH. V Square Quantitative Management LLC acquired a new stake in Guardant Health in the 4th quarter worth about $27,000. Chesapeake Asset Management LLC purchased a new position in shares of Guardant Health in the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health in the fourth quarter worth approximately $31,000. Elyxium Wealth LLC purchased a new stake in shares of Guardant Health during the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC raised its stake in Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health News Roundup

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.